Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
Xiaoxin X. Wang(Beijing Obstetrics and Gynecology Hospital), Moshe Levi(Georgetown University), Jill W. Verlander(University of Florida), Shinobu Miyazaki‐Anzai(University of Colorado Denver), Jeffrey B. Kopp(National Institute of Diabetes and Digestive and Kidney Diseases), Nathaniel Solis(Denver VA Medical Center), Luciano Adorini(Intercept Pharmaceuticals (United States)), Mark Pruzanski(University of Padua), Frank J. Gonzalez(National Cancer Institute), Linda Lewis(Denver VA Medical Center), Cydney Urbanek(Denver VA Medical Center), Yupanqui Caldas(Denver VA Medical Center), Yan Shen(Denver VA Medical Center), Tao Jiang(Third Affiliated Hospital of Southern Medical University), Pnina Scherzer(Hadassah Academic College), Hannah Santamaria(Denver VA Medical Center)
Cited by 187
Related Papers
Triglycerides and Cardiovascular Disease
|Circulation|2011|1.9k
Lipid Rafts Reconstituted in Model Membranes
|Biophysical Journal|2001|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
|Journal of the American Society of Nephrology|2011|856
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
|Nature Genetics|2008|706